Events & Webinars

ASCO-GU 2023: The DEAR study

Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Description

In this on-demand video,

Professor Robert Jones

gives an update on a congress highlight presented at the 2023 American Society of Clinical Oncology Genitourinary (ASCO-GU) Symposium. Professor Jones discusses the results of the DEAR study on the real-world utilisation and outcomes of darolutamide, enzalutamide, and apalutamide in patients with nmCRPC, including discontinuation data and data on progression to metastatic castration-resistant prostate cancer (mCRPC).

NUBEQA Prescribing Information

Speakers

Professor Robert Jones
Professor Robert Jones
Professor Jones is Director, Cancer Clinical Trials Unit for Scotland, professor of clinical cancer research at the University of Glasgow and a consultant medical oncologist at the Beatson West of Scotland Cancer Centre.
After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials as well as collaborative translational research. He currently chairs the UK National Clinical Research Institute’s Bladder and Renal research group.

BAUS 2024: Imaging and nmCRPC

NUBEQA® (darolutamide)

NUBEQA Prescribing Information

PP-NUB-GB-2081, January 2025

BAUS 2024: Urology and Oncology in Partnership

NUBEQA® (darolutamide)

NUBEQA Prescribing Information

PP-NUB-GB-2080, January 2025

BAUS 2024: Management of CV toxicity and bone health

NUBEQA® (darolutamide)

NUBEQA Prescribing Information

PP-NUB-GB-2079, January 2025

PP-NUB-GB-2022 | January 2025